NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q3 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $0 | – | 9 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 9 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | – | 9 | +12.5% | 0.00% | – |
| Q4 2021 | $0 | – | 8 | +700.0% | 0.00% | – |
| Q4 2020 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q3 2020 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q2 2020 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | -100.0% | 1 | -100.0% | 0.00% | -100.0% |
| Q3 2019 | $2,348,000 | -73.2% | 128,906 | -47.7% | 0.01% | +66.7% |
| Q2 2019 | $8,770,000 | +116.1% | 246,538 | +104.1% | 0.00% | -50.0% |
| Q1 2019 | $4,058,000 | +19.6% | 120,803 | +17.0% | 0.01% | 0.0% |
| Q4 2018 | $3,394,000 | -50.3% | 103,271 | -7.8% | 0.01% | -50.0% |
| Q3 2018 | $6,825,000 | +35.0% | 111,980 | +8.1% | 0.01% | +20.0% |
| Q2 2018 | $5,056,000 | -37.2% | 103,553 | +36.7% | 0.01% | -44.4% |
| Q1 2018 | $8,048,000 | – | 75,759 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |